Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender
- 8 September 2016
- journal article
- Published by Elsevier BV in Biochemical Pharmacology
- Vol. 119, 76-84
- https://doi.org/10.1016/j.bcp.2016.09.003
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Pharmacogenetics of dabigatran etexilate interindividual variabilityThrombosis Research, 2016
- Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humansClinical Pharmacology & Therapeutics, 2015
- The effects of CES1A2 A(−816)C and CYP2C19 loss-of-function polymorphisms on clopidogrel response variability among Chinese patients with coronary heart diseasePharmacogenetics and Genomics, 2014
- Identification of Carboxylesterase-Dependent Dabigatran Etexilate HydrolysisDrug Metabolism and Disposition, 2013
- Carboxylesterase 1 as a Determinant of Clopidogrel Metabolism and ActivationThe Journal of pharmacology and experimental therapeutics, 2012
- Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in HumansClinical Pharmacology & Therapeutics, 2012
- Characterization of Recombinant Human Carboxylesterases: Fluorescein Diacetate as a Probe Substrate for Human Carboxylesterase 2Drug Metabolism and Disposition, 2011
- Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHDNeuropharmacology, 2009
- Two CES1 Gene Mutations Lead to Dysfunctional Carboxylesterase 1 Activity in Man: Clinical Significance and Molecular BasisAmerican Journal of Human Genetics, 2008
- Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip ReplacementThe Journal of Clinical Pharmacology, 2005